Gynuity envisions a world in which each individual has access to safe and effective reproductive and maternal health care—delivered where, when, and how needed.
It is our mission to develop scientific, clinical and programmatic evidence in reproductive and maternal health and to advocate for its use, assuring that each individual benefits from the fruits of medical science and technology. We do this on a global scale through research, strategic partnerships, and communications for impact.
Due to COVID-19 Gynuity Health Projects is now working remotely. If you want to contact any of our staff members, please email them directly. (Staff emails are listed in our website’s staff directory.) If you want to leave a message in our attended general mailbox, please send it to firstname.lastname@example.org.
Gynuity listens to women, providers and policymakers, and works with them to create services that are safe, high quality, and person-centered. Through conversations and active collaborations, we use research to fill evidence gaps for new models of care, influence change, and advocate for improvements in policy and practice.
Our research demonstrates that simple, safe, and effective reproductive and maternal health technologies transform lives and improve outcomes for women and girls.
Through speaking, convening partners, and publishing our research, we create the synergies that trigger change in policy and practice.
Strategic communications increase the impact of our research and programmatic findings.
A repeat dose of misoprostol 800mcg following mifepristone for outpatient medical abortion at 64-70 and 71-77 days of gestation: A retrospective chart review
Multi-level pregnancy test use for medical abortion follow-up after 63 days’ gestation: Evidence from prenatal hCG data
Testing a Home-Based Model of Care Using Misoprostol for Prevention and Treatment of Postpartum Hemorrhage: Results From a Randomized Placebo-Controlled Trial Conducted in Badakhshan Province, Afghanistan
Learn about Gynuity's achievements and new programmatic directions.Read the Strategic Plan
Gynuity is providing a safe and effective way for women to access medical abortion using telemedicine.Visit the TelAbortion Website
Gynuity's image bank offers illustrations that can help articulate concepts across audiences. Available for download.View the Image Bank
Learn about medical abortion commodities in dozens of countries.Explore the database
Gynuity has been at the forefront of global women’s health since 2003.See our Achievements
Gynuity's TelAbortion Media Toolkit provides messaging and graphics for the dissemination of information about the study across media channels.View Here
In case you missed it- check out this 15 minute video by Angela M. Hill and Karen Rodriguez on the history of mifepristone policy in the U.S. featuring Gynuity president Beverly Winikoff. The video investigates baseless FDA restrictions as well as claims that overstate the danger of the drug. It’s a great refresher on the many barriers to MA access and the burden this puts onto abortion-seekers and care providers.View Video
Beverly was also featured in an episode of the podcast series Self Managed: An Abortion Story that interviews diverse perspectives on self managed abortion. In the episode, Part 3: The Abortion Pill, RU486, she outlines its invention, introduction to the American market and how the pill moves globally. Mifepristone has made an enormous impact in allowing women to independently manage their reproductive lives.View Podcast